“The Applicant evaluated the safety of pralsetinib using Sprague-Dawley rats and Cynomolgus monkeys in GLP-compliant repeat-dose toxicology studies of up to 13 weeks duration.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Pivotal GLP studies
28-day and 13-week GLP oral gavage studies in rats and cynomolgus monkeys
“The rat and cynomolgus monkey were used in GLP-compliant 28-days and 13-week repeat dose”